<DOC>
	<DOCNO>NCT01192971</DOCNO>
	<brief_summary>This phase II trial study well Apatinib work patient liver cancer .</brief_summary>
	<brief_title>A Study Apatinib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Histologically cytologic confirm advanced hepatocellular carcinoma Life expectancy 3 month . ECOG performance scale 0 2 . No cirrhosis child pugh score A At least one measurable lesion ( large 10 mm diameter spiral CT scan . Adequate hepatic , renal , heart , hematologic function ( platelet &gt; 90 × 109/L , neutrophil &gt; 1.5 × 109/L , serum creatinine ≤ 1.5mg/dl , total bilirubin within upper limit normal ( ULN ) , serum transaminase≤2.5×the ULN ) . sign date informed consent.Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Pregnant breastfeed woman History second malignancy within 3 year except cure basal cell carcinoma skin carcinoma insitu uterine cervix Any factor influence usage oral administration Evidence CNS metastasis Intercurrence one following : hypertension , coronary artery disease , arrhythmia heart failure Receiving therapy thrombolysis anticoagulation Abuse alcohol drug Less 4 week last clinical trial Disability serious uncontrolled intercurrence infection . Treatment potent CYP3A4 inhibitor inducer 7 12 day respectively , prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hcc , apatinib , phase II , cancer</keyword>
</DOC>